Screener
Palvella Therapeutics PVLA Operating Lease Liabilities
Operating Lease Liabilities at other companies
Other financials
Where this comes from
Reported directly by Palvella Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseLiabilityNoncurrent.
The source filing: Palvella Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210463
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Current portion of operating lease liability | 209 | 202 |
| Accrued expenses and other current liabilities | 3,463 | 4,351 |
| Total current liabilities | 9,115 | 11,344 |
| Long-term portion of operating lease liability | 375 | 431 |
| Royalty agreement liability | 19,799 | 17,760 |
| Derivative liabilities – royalty agreement | 2,157 | 2,041 |
| Total liabilities | 31,446 | 31,576 |
| Commitments and contingencies (Note 8) |
Item 1. Financial Statements.
FAQ
- What is Palvella Therapeutics's operating lease liabilities?
- Palvella Therapeutics (PVLA) reported operating lease liabilities of $375K in Q1 2026.
- What is the long-term trend for Palvella Therapeutics's operating lease liabilities?
- Over 5 years (2020 to 2025), Palvella Therapeutics's operating lease liabilities has grown at a -51.4% compound annual growth rate (CAGR), from $15.93M to $431K.
- What does operating lease liabilities mean?
- Long-term portion of operating lease obligations extending beyond one year, representing committed future rent payments.
Ask your AI about Palvella Therapeutics's operating lease liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude